Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis.

Alberts, Ian Leigh; Seide, Svenja Elizabeth; Mingels, Clemens; Bohn, Karl Peter; Shi, Kuangyu; Zacho, Helle D; Rominger, Axel; Afshar-Oromieh, Ali (2021). Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. European journal of nuclear medicine and molecular imaging, 48(9), pp. 2978-2989. Springer 10.1007/s00259-021-05210-9

[img]
Preview
Text
259_2021_Article_5210.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

PURPOSE

Many radiotracers are currently available for the detection of recurrent prostate cancer (rPC), yet many have not been compared head-to-head in comparative imaging studies. There is therefore an unmet need for evidence synthesis to guide evidence-based decisions in the selection of radiotracers. The objective of this study was therefore to assess the detection rate of various radiotracers for the rPC.

METHODS

The PUBMED, EMBASE, and the EU and NIH trials databases were searched without date or language restriction for comparative imaging tracers for 13 radiotracers of principal interest. Key search terms included 18F-PSMA-1007, 18F-DCPFyl, 68Ga-PSMA-11, 18F-PSMA-11, 68Ga-PSMA-I&T, 68Ga-THP-PSMA, 64Cu-PSMA-617, 18F-JK-PSMA-7, 18F-Fluciclovine, 18F-FABC, 18F-Choline, 11C-Choline, and 68Ga-RM2. Studies reporting comparative imaging data in humans in rPC were selected. Single armed studies and matched pair analyses were excluded. Twelve studies with eight radiotracers were eligible for inclusion. Two independent reviewers screened all studies (using the PRISMA-NMA statement) for inclusion criteria, extracted data, and assessed risk of bias (using the QUADAS-2 tool). A network meta-analysis was performed using Markov-Chain Monte Carlo Bayesian analysis to obtain estimated detection rate odds ratios for each tracer combination.

RESULTS

A majority of studies were judged to be at risk of publication bias. With the exception of 18F-PSMA-1007, little difference in terms of detection rate was revealed between the three most commonly used PSMA-radiotracers (68Ga-PSMA-11, 18F-PSMA-1007, 18F-DCFPyl), which in turn showed clear superiority to choline and fluciclovine using the derived network.

CONCLUSION

Differences in patient-level detection rates were observed between PSMA- and choline-radiotracers. However, there is currently insufficient evidence to favour one of the four routinely used PSMA-radioligands (PSMA-11, PSMA-1007, PSMA-I&T, and DCFPyl) over another owing to the limited evidence base and risk of publication bias revealed by our systematic review. A further limitation was lack of reporting on diagnostic accuracy, which might favour radiotracers with low specificity in an analysis restricted only to detection rate. The NMA derived can be used to inform the design of future clinical trials and highlight areas where current evidence is weak.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Alberts, Ian Leigh; Mingels, Clemens; Bohn, Karl Peter; Shi, Kuangyu; Rominger, Axel Oliver and Afshar Oromieh, Ali

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1619-7089

Publisher:

Springer

Language:

English

Submitter:

Daria Vogelsang

Date Deposited:

05 Jan 2022 17:42

Last Modified:

05 Jan 2022 17:42

Publisher DOI:

10.1007/s00259-021-05210-9

PubMed ID:

33550425

Uncontrolled Keywords:

Choline Comparative imaging Network meta-analysis PET/CT PSMA Positron emission tomography Radiotracers

BORIS DOI:

10.48350/161326

URI:

https://boris.unibe.ch/id/eprint/161326

Actions (login required)

Edit item Edit item
Provide Feedback